What is Eradivir?
Eradivir operates at the intersection of biotechnology and immunology, specializing in the development of small-molecule therapeutics. The company's core innovation, the BAiT technology, functions by tethering a patient's immune cells directly to diseased cells, enabling rapid and selective destruction. This mechanism represents a sophisticated approach to treating complex conditions, including viral infections and various forms of oncology. By focusing on the modularity of its small-molecule toolkit, Eradivir aims to establish a scalable pharmaceutical platform capable of addressing a broad spectrum of therapeutic indications, positioning itself as a high-potential player in the next generation of precision medicine.
How much funding has Eradivir raised?
Eradivir has raised a total of $20.3M across 2 funding rounds:
Series A
$10.3M
Private Equity
$10M
Series A (2024): $10.3M, investors not publicly disclosed
Private Equity (2025): $10M, investors not publicly disclosed
Key Investors in Eradivir
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Eradivir?
With this major enterprise-level funding, Eradivir is well-positioned to advance its lead candidates through critical development milestones. The strategic roadmap likely involves scaling manufacturing capabilities for its small-molecule compounds and initiating rigorous clinical trials to validate the efficacy of the BAiT platform in human subjects. Furthermore, the company is expected to leverage this capital to strengthen its intellectual property portfolio and potentially pursue strategic partnerships with larger pharmaceutical entities to expedite the commercialization of its therapeutic assets. The focus remains on transforming the landscape of immune-mediated disease treatment through scientific rigor and technological precision.
See full Eradivir company page
